Activation of the constitutive androstane receptor decreases HDL in wild-type and human apoA-I transgenic mice

Journal of Lipid Research

Volumn 49, Issue 8, 2008, Pages 1682-1691

  Masson, David ^a,b   Qatanani, Mohamed ^c   Sberna, Anne Laure ^a,b   Xiao, Rui ^c   de Barros, Jean Paul Pais ^a,b   Grober, Jacques ^a,b   Deckert, Valerie ^a,b   Athias, Anne ^a,b   Gambert, Philippe ^a,b   Lagrost, Laurent ^a,b   Moore, David D ^c   Assem, Mahfoud ^d  

^a Chu   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

1,4 bis 2 (3,5 dichloropyridyloxy) benzene; Apolipoprotein A I; Bile acids; Cholesterol

Indexed keywords

1,4 BIS(3,5 DICHLORO 2 PYRIDYLOXY)BENZENE; APOLIPOPROTEIN A1; CONSTITUTIVE ANDROSTANE RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; 1,4 BIS(2 (3,5 DICHLOROPYRIDYLOXY))BENZENE; 1,4-BIS(2-(3,5-DICHLOROPYRIDYLOXY))BENZENE; ABCC4 PROTEIN, MOUSE; CELL RECEPTOR; HIGH DENSITY LIPOPROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; PYRIDINE DERIVATIVE; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DOWN REGULATION; LIPID DIET; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; ANIMAL; BLOOD; FAT INTAKE; GENETICS; HUMAN; METABOLISM; NUCLEOTIDE SEQUENCE; PHYSIOLOGY;

ANIMALS; APOLIPOPROTEIN A-I; BASE SEQUENCE; CHOLESTEROL, HDL; DIETARY FATS; DOWN-REGULATION; HUMANS; LIPOPROTEINS, HDL; MICE; MICE, TRANSGENIC; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PROMOTER REGIONS (GENETICS); PYRIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 51449107194     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M700374-JLR200     Document Type: Article

References (37)

1. Willson, T. M., and S. A. Kliewer. 2002. PXR, CAR and drug metabolism. Nat. Rev. Drug Discov. 1: 259-266.
2. Xie, W., M. F. Yeuh, A. Rodominska-Pandya, S. P. S. Saini, Y. Negishi, B. S. Bottroff, G. Y. Cabrera, R. H. Tukey, and R. M. Evans. 2003. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc. Natl. Acad. Sci. USA. 100: 4150-4155.
3. Qatanani, M., and D. D. Moore. 2005. CAR, the continuously advancing receptor, in drug metabolism and disease. Curr. Drug Metab. 6: 329-339.
4. Guo, G. L., G. Lambert, M. Negishi, J. M. Ward, H. B. Brewer, S. A. Kliewer, F. J. Gonzalez, and C. J. Sinal. 2003. Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J. Biol. Chem. 278: 45062-45071.
5. Uppal, H., D. Toma, S. P. Saini, S. Ren, T. J. Jones, and W. Xie. 2005. Combined loss of orphan receptors PXR and CAR heightens sensitivity to toxic bile acids in mice. Hepatology. 41: 168-176.
6. Stedman, C. A., C. Liddle, S. A. Coulter, J. Sonoda, J. G. Alvarez, D. D. Moore, R. M. Evans, and M. Downes. 2005. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc. Natl. Acad. Sci. USA. 102: 2063-2068.
7. Lehmann, D. D., M. A. McKee, T. M. Watson, W. J. T. Moore, and S. A. Kliewer. 1998. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102: 1016-1023.
8. Aynaci, F. M., F. Orhan, A. Orem, S. Yildirmis, and Y. Cedik. 2001. Effect of antiepileptic drugs on plasma lipoprotein (a) and other lipid levels in childhood. J. Child Neurol. 16: 367-369.
9. Romaschin, A. D., and D. M. Goldberg. 1987. Effect of phenobarbital upon serum cholesterol lipoprotein fractions of three rodent species. Clin. Physiol. Biochem. 5: 77-84.
10. Jackson, J. P., S. S. Ferguson, R. Moore, M. Negishi, and J. A. Goldstein. 2004. The constitutive active/androstane receptor regulates phenytoin induction of Cyp2C29. Mol. Pharmacol. 65: 1397-1404.
11. Wang, H., S. Faucette, R. Moore, T. Sueyoshi, M. Negishi, and E. Le Cluyse. 2004. Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J. Biol. Chem. 279: 29295-29301.
12. Kobayashi, K., S. Yamagami, T. Higuchi, M. Hosokawa, and K. Chiba. 2004. Key structural features of ligands for activation of human pregnane X receptor. Drug Metab. Dispos. 32: 468-472.
13. Miller, M., R. G. Burgan, L. Osterlund, J. P. Segrest, and D. W. Garber. 1995. A prospective, randomized trial of phenytoin in nonepileptic subjects with reduced HDL cholesterol. Arterioscler. Thromb. Vasc. Biol. 15: 2151-2156.
14. Goerdt, C., M. Keith, and H. B. Rubins. 1995. Effects of phenytoin on plasma high-density lipoprotein cholesterol levels in men with low levels of high-density lipoprotein cholesterol. J. Clin. Pharmacol. 35: 767-775.
15. Wei, P., J. Zhang, M. Egan-Hafley, S. Liang, and D. D. Moore. 2000. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature. 407: 920-923.
16. Rubin, E. M., B. Y. Ishida, S. M. Clift, and R. M. Krauss. 1991. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc. Natl. Acad. Sci. USA. 88: 434-438.
17. Tzameli, I., P. Pissios, E. G. Schuetz, and D. D. Moore. 2000. The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. Mol. Cell. Biol. 20: 2951-2958.
18. Gautier, T., D. Masson, M. C. Jong, L. Duverneuil, N. Le Guern, V. Deckert, J. P. Pais de Barros, L. Dumont, A. Bataille, Z. Zak, et al. 2002. Apolipoprotein CI deficiency markedly augments plasma lipoprotein changes mediated by human cholesteryl ester transfer protein (CETP) in CETP transgenic/ApoCI-knocked out mice. J. Biol. Chem. 277: 31354-31363.
19. Matthews, C. M. 1957. The theory of tracer experiments with 131Ilabelled plasma proteins. Phys. Med. Biol. 2: 36-53.
20. Srivastava, R. A. K., N. Srivastava, and M. Averna. 2000. Dietary cholic acid lowers plasma levels of mouse and human apolipoprotein A-I primarily via a transcriptional mechanism. Eur. J. Biochem. 267: 4272-4280.
21. Berthou, L., N. Duverger, F. Emmanuel, S. Langouet, J. Auwerx, A. Guillouzo, J. C. Fruchart, E. Rubin, P. Denefle, B. Staels, et al. 1996. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J. Clin. Invest. 97: 2408-2416.
22. Rubin, E. M., R. M. Krauss, E. A. Spangler, J. G. Verstuyft, and S. M. Clift. 1991. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 353: 265-267.
23. Assem, M., E. G. Schuetz, M. Leggas, D. Sun, K. Yasuda, G. Reid, N. Zelcer, M. Adachi, S. Strom, R. M. Evans, et al. 2004. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J. Biol. Chem. 279: 22250-22257.
24. Goodwin, B., E. Hodgson, D. J. D'Costa, G. R. Robertson, and C. Liddle. 2002. Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol. Pharmacol. 62: 359-365.
25. Zhang, J., W. Huang, M. Qatanani, R. M. Evans, and D. D. Moore. 2004. The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J. Biol. Chem. 279: 49517-49522.
26. Saini, S. P., J. Sonoda, L. Xu, D. Toma, H. Uppal, Y. Mu, S. Ren, D. D. Moore, R. M. Evans, and W. Xie. 2004. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol. Pharmacol. 65: 292-300.
27. Peet, D. J., S. D. Turley, W. Ma, B. A. Janowski, J. M. Lobaccaro, R. E. Hammer, and D. J. Mangelsdorf. 1998. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell. 93: 693-704.
28. Alberti, S., G. Schuster, P. Parini, D. Feltkamp, U. Diczfalusy, M. Rudling, B. Angelin, I. Bjorkhem, S. Pettersson, and J. A. Gustafsson. 2001. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J. Clin. Invest. 107: 565-573.
29. Ueda, A., H. Hamadeh, H. K. Webb, Y. Yamamoto, T. Sueyoshi, C. A. Afshari, J. M. Lehmann, and M. Negishi. 2002. Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. Mol. Pharmacol. 61: 1-6.
30. Handschin, C., M. Podvinec, R. Amherd, R. Looser, J. C. Ourlin, and U. A. Meyer. 2002. Cholesterol and bile acids regulate xenosensor signaling in drug-mediated induction of cytochromes P450. J. Biol. Chem. 277: 29561-29567.
31. Li, T., and J. Y. Chiang. 2004. Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7 alpha-hydroxylase gene transcription. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G74-G84.
32. Bhalla, S., C. Ozalp, S. Fang, L. Xiang, and J. K. Kemper. 2004. Ligand-activated pregnane X receptor interferes with HNF-4 signaling by targeting a common coactivator PGC-1alpha. Functional implications in hepatic cholesterol and glucose metabolism. J. Biol. Chem. 279: 45139-45147.
33. Miao, J., F. Sungsoon, Y. Bae, and J. K. Kemper. 2006. Functional inhibitory cross-talk between constitutive androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metabolism is mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1a. J. Biol. Chem. 281: 14537-14546.
34. Delerive, P., C. M. Galardi, J. E. Bisi, E. Nicodeme, and B. Goodwin. 2004. Identification of liver receptor homolog-1 as a novel regulator of apolipoprotein AI gene transcription. Mol. Endocrinol. 18: 2378-2387.
35. Harnish, D. C., S. Malik, and S. K. Karathanasis. 1994. Activation of apolipoprotein AI gene transcription by the liver-enriched factor HNF-3. J. Biol. Chem. 269: 28220-28226.
36. Claudel, T., E. Sturm, H. Duez, I. P. Torra, A. Sirvent, V. Kosykh, J. C. Fruchart, J. Dallongeville, D. W. Hum, F. Kuipers, et al. 2002. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J. Clin. Invest. 109: 961-971.
37. Tzameli, I., and V. I. Zannis. 1996. Binding specificity and modulation of the apoA-I promoter activity by homo- and heterodimers of nuclear receptors. J. Biol. Chem. 271: 8402-8415.